Boshra Maria N, Moharram Hossam M, Khairat Yehia M, Moustafa M Tarek A
Department of Ophthalmology, Minia University, Minya, Egypt.
Oman J Ophthalmol. 2025 Feb 25;18(1):33-39. doi: 10.4103/ojo.ojo_159_24. eCollection 2025 Jan-Apr.
The aim of the study is to compare the effects of three mydriatic agents on anterior segment parameters and intraocular pressure (IOP) in pseudoexfoliation (PEX) patients and compare the results with healthy controls.
This cross-sectional study involved 25 PEX and 16 control patients. Each received three dilating drops (phenylephrine, tropicamide, and cyclopentolate) with eye examinations before and after (over 3 weeks). The measured parameters included IOP, gonioscopy grading, and Scheimpflug imaging analysis of anterior chamber depth, anterior chamber volume, anterior chamber angle, pupillary diameter (PD), central corneal thickness (CCT), and corneal volume.
The mean age was 66.12 years in the PEX group and 55 years in the control group. There were no significant differences between the groups in baseline parameters, except for CCT being significantly thicker in the control group ( = 0.049). After 2 h of using the dilating drops, the PEX group showed no change in CCT and gonioscopy measurement while all the other tested parameters showed a significant increase. Phenylephrine caused the greatest increase in pupil diameter. Correlation analysis of PD versus other parameters in both groups showed only a negative significant correlation between PD and IOP when using tropicamide on the PEX patients.
All three dilating drops are effective in dilating PEX patients. Phenylephrine is the most effective and ideal for both clinics and surgeries. Cyclopentolate is the least effective dilator in PEX patients compared to healthy controls. Tropicamide 1% provides a good balance between pupil dilation and minimal IOP elevation, making it safer for PEX patients.
本研究旨在比较三种散瞳剂对假性剥脱(PEX)患者眼前节参数和眼压(IOP)的影响,并将结果与健康对照者进行比较。
这项横断面研究纳入了25例PEX患者和16例对照患者。每位患者均接受三种散瞳滴眼液(去氧肾上腺素、托吡卡胺和环喷托酯),并在用药前后(超过3周)进行眼部检查。测量参数包括眼压、前房角镜分级以及前房深度、前房容积、前房角、瞳孔直径(PD)、中央角膜厚度(CCT)和角膜容积的Scheimpflug成像分析。
PEX组的平均年龄为66.12岁,对照组为55岁。除对照组的CCT显著更厚(P = 0.049)外,两组的基线参数无显著差异。使用散瞳滴眼液2小时后,PEX组的CCT和前房角镜测量无变化,而所有其他测试参数均显著增加。去氧肾上腺素导致瞳孔直径增加最大。两组中PD与其他参数的相关性分析显示,在PEX患者中使用托吡卡胺时,PD与眼压之间仅存在显著负相关。
所有三种散瞳滴眼液对PEX患者均有效。去氧肾上腺素对临床和手术而言都是最有效且理想的。与健康对照者相比,环喷托酯是PEX患者中效果最差的散瞳剂。1%的托吡卡胺在瞳孔散大和眼压升高最小之间提供了良好的平衡,对PEX患者更安全。